View Older Stories View More Recent Stories

Apr 19, 2016 02:08PM Merck (MRK) Comments on Blueprint PD-L1 Assay Comparison Project; Encouraged by Findings
Apr 19, 2016 02:05PM Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Apr 18, 2016 08:05AM Merck (MRK) Receives FDA Breakthrough Therapy Designation for KEYTRUDA in cHL
Apr 18, 2016 08:00AM Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
Apr 18, 2016 06:51AM Merck (MRK) Preents Data from Two ZEPATIER Phase 3s; High SVR Demonstrated
Apr 16, 2016 01:00AM Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Apr 14, 2016 06:22AM Merck (MRK) Announces Strong Data from C-EDGE Head-to-Head Study
Apr 14, 2016 01:00AM Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Apr 13, 2016 07:01AM Merck (MRK) Announces FDA Acceptance of KEYTRUDA sBLA; Priority Review Granted
Apr 13, 2016 07:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
Apr 8, 2016 08:00AM Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
Apr 7, 2016 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016
Apr 6, 2016 08:03AM Merck (MRK) Will Present New KEYTRUDA Data at AACR Annual Meeting
Apr 6, 2016 08:00AM Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
Apr 5, 2016 08:22AM Pfizer (PFE), Merck (MRK) Treat First Patient in Avelumab Phase 3
Apr 5, 2016 08:03AM Advaxis (ADXS), Merck (MRK) Complete First Two Dose Escalations in KEYNOTE-046 Trial
Apr 5, 2016 08:00AM Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
Apr 1, 2016 08:00AM Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency
Mar 30, 2016 07:00AM Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
Mar 9, 2016 04:00PM Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening Treatment Access for Veterans with Chronic Hepatitis C Infection
Mar 8, 2016 08:04AM Sanofi Pasteur (SNY) and Merck (MRK) to End Joint Vaccines Operations in Europe
Mar 8, 2016 08:00AM Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strateg
Mar 7, 2016 04:30PM Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire
Mar 7, 2016 08:10AM Merck (MRK) Annnounces FDA Acceptance of KEYTRUDA sBLA
Mar 7, 2016 08:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Mar 4, 2016 10:00AM Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa
Feb 23, 2016 01:30PM Merck Announces Second-Quarter 2016 Dividend
Feb 22, 2016 11:30AM Merck Puts Spotlight on Women's Health and Well-being
Feb 22, 2016 08:07AM Merck (MRK) Announces ISENTRESS Phase 3 Met Primary Efficacy Endpoint in HIV-1
Feb 22, 2016 08:00AM Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
Feb 17, 2016 06:45AM Diplomat Pharmacy (DPLO) Begins Filling Prescriptions for ZEPATIER as HCV Treatment (MRK)
Feb 16, 2016 07:02AM Merck (MRK) Announces Receipt of CRL for ZETIA and VYTORIN NDA
Feb 15, 2016 05:30PM Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Feb 4, 2016 08:00AM FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving
Feb 3, 2016 06:45AM Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
Jan 29, 2016 06:18AM Merck (MRK) Announces FDA Approval of ZEPATIER as Genotype 1, 4 HCV Treatment
Jan 28, 2016 07:01PM Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Jan 28, 2016 06:59PM Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Jan 27, 2016 08:31AM Merck (MRK) Announces FDA Acceptance of Bezlotoxumab BLA in C. difficile Prevention
Jan 27, 2016 08:30AM Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
Jan 25, 2016 09:32AM Pre-Open Stock Movers 01/25: (AFMD) (GRUB) (SUNE) (TYC) Higher; (OMED) (NVAX) (TWTR) Lower (more...)
Jan 19, 2016 10:00AM Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
Jan 15, 2016 07:00AM Merck (MRK) Announces Resolation to Vioxx Securities Class Action; Will Pay $830M
Jan 15, 2016 07:00AM Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
Jan 11, 2016 04:08PM Merck (MRK) Announces Acquisition of IOmet
Jan 11, 2016 04:08PM Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
Jan 8, 2016 08:00AM Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 5, 2016 08:00AM Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3
Jan 4, 2016 08:00AM Merck to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Dec 23, 2015 08:34AM Merck (MRK) Announces WHO Acceptance of EUAL for Ebola Zaire Vaccine
View More Recent Stories View Older Stories